Analysis of related factors influencing postoperative recurrence of adenomyosis treated with HIFU

review OA: closed CC0
AI-generated summary by gemini-2.5-flash-lite, 2026-07-09

This study analyzed 308 adenomyosis patients treated with HIFU, finding parity, uterine size, diffuse lesions, and ablation rate influenced recurrence, while TCM combined therapy was protective.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-09 · read from full text

This retrospective real-world study analyzed clinical follow-up of 308 patients with adenomyosis treated with high-intensity focused ultrasound (HIFU) at a single center, tracking symptom management (dysmenorrhea and menorrhagia) and postoperative recurrence over 6–36 months using multivariable logistic regression. At 6 months, efficacy for dysmenorrhea and menorrhagia management was 86.7% and 89.3%, respectively, with recurrence rates increasing across time windows, and no effect on prognosis from variables including age, disease course, gravidity, HIFU irradiation duration/intensity, follow-up time, lesion location, and preoperative menstrual volume. Multivariate analysis identified parity, uterine size, diffuse lesion type and ablation rate (with diffuse type and higher ablation rate associated with lower relapse risk), and a protective/beneficial association for combined traditional Chinese medicine (TCM) treatment, while reporting limitations including loss to follow-up of 23% of participants. This paper is centrally about adenomyosis—specifically postoperative recurrence and prognostic factors after HIFU, including symptom outcomes and the role of adjunct TCM.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To analyze the efficacy of high-intensity focused ultrasound (HIFU) for adenomyosis and postoperative recurrence and its influencing factors. METHODS: Clinical and follow-up data of 308 patients with adenomyosis who were treated with HIFU in Haifu Center, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from September 2017 to January 2022 were retrospectively analyzed. The recurrence of adenomyosis and the efficacy of HIFU at 6 months after surgery were followed up. To explore factors influencing postoperative prognosis and recurrence, the following variables were analyzed: patients' age, course of disease, gravidity and parity, size of the uterus, duration of HIFU, duration of irradiation, treatment intensity, dysmenorrhea score, time of follow-up, combined treatment of traditional Chinese medicine (TCM), western medicine adjuvant treatment, lesion location and type, and menorrhagia. RESULTS: Among the 308 patients, 238 (77%) were followed up from 6 to 36 months, with an average follow-up time of 15.24 ± 9.97 months. The other 70 (23%) were lost to follow-up. At 6-month after surgery, efficacy rates of dysmenorrhea and menorrhagia management were 86.7% and 89.3%, respectively. Postoperative recurrence rates were 4.8% (1-12 months), 9.0% (12-24 months), and 17.0% (24-36 months) for dysmenorrhea; and 6.3% (1-12 months), 2.4% (12-24 months), and 12.2% (24-36 months) for menorrhagia. Multivariate logistic regression analyses showed that parity (P = 0.043, OR = 1.773, 95% CI 1.018-3.087), uterine size (P = 0.019, OR = 1.004, 95% CI 1.001-1.007), combined treatment of TCM (P = 0.047, OR = 1.846, 95% CI 1.008-3.381), diffuse lesion type (P = 0.013, OR = 0.464, 95% CI 0.254-0.848) and ablation rate (P = 0.015, OR = 0.481, 95%CI 0.267-0.868) were prognostic factors (P < 0.05). Age, course of disease, gravidity, duration of HIFU, duration of irradiation, treatment intensity, preoperative dysmenorrhea score, time of follow-up, western medicine adjuvant therapy, lesion location, and preoperative menstrual volume had no effect on prognosis (P > 0.05). CONCLUSION: HIFU can effectively relieve dysmenorrhea and reduce menstrual volume in patients with adenomyosis. Parity, uterine size, lesion type (diffuse), and ablation rate are risk factors for symptom recurrence after HIFU, while the combination of TCM therapy is a protective factor for relapse. We, therefore, recommend TCM in the adjuvant setting after HIFU according to patient condition.
Full text 12,704 characters · extracted from oa-doi-fallback · 6 sections · click to expand

Abstract

Objective To analyze the efficacy of high-intensity focused ultrasound (HIFU) for adenomyosis and postoperative recurrence and its influencing factors.

Methods

Clinical and follow-up data of 308 patients with adenomyosis who were treated with HIFU in Haifu Center, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine from September 2017 to January 2022 were retrospectively analyzed. The recurrence of adenomyosis and the efficacy of HIFU at 6 months after surgery were followed up. To explore factors influencing postoperative prognosis and recurrence, the following variables were analyzed: patients’ age, course of disease, gravidity and parity, size of the uterus, duration of HIFU, duration of irradiation, treatment intensity, dysmenorrhea score, time of follow-up, combined treatment of traditional Chinese medicine (TCM), western medicine adjuvant treatment, lesion location and type, and menorrhagia.

Results

Among the 308 patients, 238 (77%) were followed up from 6 to 36 months, with an average follow-up time of 15.24 ± 9.97 months. The other 70 (23%) were lost to follow-up. At 6-month after surgery, efficacy rates of dysmenorrhea and menorrhagia management were 86.7% and 89.3%, respectively. Postoperative recurrence rates were 4.8% (1–12 months), 9.0% (12–24 months), and 17.0% (24–36 months) for dysmenorrhea; and 6.3% (1–12 months), 2.4% (12–24 months), and 12.2% (24–36 months) for menorrhagia. Multivariate logistic regression analyses showed that parity (P = 0.043, OR = 1.773, 95% CI 1.018–3.087), uterine size (P = 0.019, OR = 1.004, 95% CI 1.001–1.007), combined treatment of TCM (P = 0.047, OR = 1.846, 95% CI 1.008–3.381), diffuse lesion type (P = 0.013, OR = 0.464, 95% CI 0.254–0.848) and ablation rate (P = 0.015, OR = 0.481, 95%CI 0.267–0.868) were prognostic factors (P < 0.05). Age, course of disease, gravidity, duration of HIFU, duration of irradiation, treatment intensity, preoperative dysmenorrhea score, time of follow-up, western medicine adjuvant therapy, lesion location, and preoperative menstrual volume had no effect on prognosis (P > 0.05).

Conclusion

HIFU can effectively relieve dysmenorrhea and reduce menstrual volume in patients with adenomyosis. Parity, uterine size, lesion type (diffuse), and ablation rate are risk factors for symptom recurrence after HIFU, while the combination of TCM therapy is a protective factor for relapse. We, therefore, recommend TCM in the adjuvant setting after HIFU according to patient condition. Similar content being viewed by others

References

2020 Chinese expert consensus on diagnosis and treatment of adenomyosis [J]. Chin J Obstetrics and Gynecology, 55(06), 376–383 American College of Obstetricians and Gynecologists (2008) ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 112(2Pt1):387–400 Siedek F, Yeo SY, Heijman E et al (2019) Magnetic resonance-guided high-intensity focused ultrasound(MR-HIFU):overview of emerging applications(part2). Rofo-Fortschr Rontg 191:531–539 Mingzhu Ye, Min X (2019) Application of high intensity focused ultrasound in the treatment of adenomyosis. Chin J Pract Gynecol Obstet 35(05):522–527 ((in Chinese)) Xin L, Wei W, Yang W et al (2015) Long-term efficacy of focused ultrasound ablation for adenomyosis. Chin J Obstet Gynecol 50(12):944–946 Cheung VY (2017) Current status of high-intensity focused ultrasound for the management of uterine adenomyosis. Ultrasonography 36(2):95–102 Lee JS, Hong GY, Lee KH (2019) Safety and efficacy of ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroids and adenomyosis. Ultrasound Med Biol 45(12):3214–3221 Marques ALS, Andres MP, Kho RM, Abrão MS (2020) Is high-intensity focused ultrasound effective for the treatment of adenomyosis? A systematic review and meta-analysis. J Minim Invasive Gynecol 27(2):332–343. https://doi.org/10.1016/j.jmig.2019.07.029. (Epub 2019 Aug 1 PMID: 31377454) Lee JS, Hong GY, Park BJ, Kim TE (2015) Ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroid and adenomyosis: a single center experience from the Republic of Korea. Ultrason Sonochem 27:682–687. https://doi.org/10.1016/j.ultsonch.2015.05.033. (Epub 2015 May 27 PMID: 26072367) Yaping Xu, Zhan Z, Yi Li et al (2021) MRI evaluation and influencing factors analysis of early uterine seromusometrium injury after high intensity focused ultrasound ablation of adenomyosis. Chin J Clin Ob Gyn 22(04):411–413 Baini X, Weiping W, Xuexing Z (2021) Analysis of influencing factors of recurrence after laparoscopic adenomyosis lesion resection. Chin Matern Child Health Care 36(02):297–300 Younes G, Tulandi T (2018) Conservative surgery for adenomyosis and results:a systematic review. J Minim Invasive Gynecol 25(2):265–276 Bulun SE, Yildiz S, Adli M, Wei JJ (2021) Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update 27(6):1086–1097. https://doi.org/10.1093/humupd/dmab017.PMID:34131719;PMCID:PMC8543024 Ya C, Ying W, Wanping Z (2021) The relationship between serum CA199 and CA125 levels and the characteristics of adenomyosis [J]. Chin Matern Child Health 36(20):4716–4719 Pan Z (2018) Clinical effect analysis of laparoscopic adenomyosis lesion resection combined with gonadotropin-releasing hormone agonist in the treatment of adenomyosis. Chin Med Guide 16(21):149–150 Lu Dajiang Fu, Qiang ZF, Lili C, Junwen W, Danhe Y (2016) Analysis of influencing factors of adenomyosis. Appl Modern Med China 10(18):97–98 Jieru Xu (2020) Analysis of influencing factors of recurrence after laparoscopic adenomyosis lesion resection. J Appl Gynecol Endocrinol 7(06):12+19 Chen Liping Lu, Fajin ZY et al (2020) The influencing factors of high intensity focused ultrasound in the treatment of uterine fibroids. Magn Reson Imag 11(11):1028 Keserci B, Duc NM (2018) Magnetic resonance imaging features influencing high-intensity focused ultrasound ablation of adenomyosis with a nonperfused volume ratio of≥90% as a measure of clinical treatment success: retrospective multivariate analysis. Int J Hyperthermia 35(1):626–636. https://doi.org/10.1080/02656736.2018.1516301. (Epub 2018 Oct 11 PMID: 30307340) Gong C, Setzen R, Liu Z, Liu Y, Xie B, Aili A, Zhang L (2017) High intensity focused ultrasound treatment of adenomyosis: the relationship between the features of magnetic resonance imaging on T2 weighted images and the therapeutic efficacy. Eur J Radiol 89:117–122. https://doi.org/10.1016/j.ejrad.2017.02.001. (Epub 2017 Feb 2 PMID: 28267526) Mingzhu Y, Min X (2013) Analysis of related factors affecting the efficacy of ultrasound ablation of adenomyosis. Chin J Appl Gynecol Obstet 29(09):748–751 (in Chinese with English abstract) Mingzhu Ye, Xinliang D, Xiaogang Z et al (2016) Clinical study of high intensity focused ultrasound ablation combined with GnRH-a and LNG-IUS in the treatment of dysmenorrhea of adenomyosis. Chin J Obstet Gynecol 51(9):643–649 Zhao Y, Luo S, Liu Y, He Y, Liu X, Guohua H, He J (2023) High intensity focused ultrasound treatment for adenomyosis: comparison of efficacy based on MRI features. Int J Hyperthermia 40(1):2197574. https://doi.org/10.1080/02656736.2023.2197574. (PMID: 37031960) Saiping M, Xinliang D (2014) Efficacy of ultrasound ablation in the treatment of adenomyosis and influencing factors of case screening [J]. Chin J Appl Gynecol Obstet 30(3):220–223 Cheng Li, Panpan Li, Fang Z et al (2019) Advantages and evaluation indexes of traditional Chinese medicine in the treatment of adenomyosis. Chin J Tradit Chin Med 37(11):2667–2671 Hua Ji, Xiaozhi C, Cuiying Z (2019) Clinical observation of Huaji-Zhitong decoction in the treatment of dysmenorrhea of adenomyosis. Shanghai Med 40(11):34–36 Qiuyan Wu, Jinhong C, Junjie X et al (2017) Clinical observation of warm acupuncture in the treatment of dysmenorrhea of adenomyosis [J]. Shanghai J Acupunct Moxib 36(04):414–418 Xinyi Z, Li T, Tingting Z (2021) Clinical research literature analysis of traditional Chinese medicine in the treatment of adenomyosis. Chin J Tradit Chin Med 36(03):1646–1649 Qian Z, Bin L, Juanjuan Ma et al (2021) Effect of clearing heat and removing stasis traditional Chinese medicine on inflammation in patients with adenomyosis after high intensity focused ultrasound. Shanghai J Tradit Chin Med 55(05):58–62 Liu J (2019) Clinical effect of high intensity focused ultrasound combined with traditional Chinese medicine in the treatment of adenomyosis. Chengdu Univ Tradit Chin Med 2020:21–40 Liu H (2020) Efficacy of high intensity focused ultrasound combined with traditional Chinese medicine in the treatment of adenomyosis. Chengdu Univ Tradit Chin Med 2021:3–24 Lingxiu F, Manli Z, Yihan Z et al (2022) Study on the treatment of adenomyosis by high-intensity focused ultrasound combined with secondary therapy of Chinese medicine. New Chin Med 54(06):192–196 Xiao-Ying Z, Ying-Shu G, Jiu-Mei C et al (2018) Effect of pre-treatment with gonadotropin -releasing hormone analogue GnRH-a on high-intensity focussed ultrasound ablation for diffuse adenomyosis: a preliminary study. Int J Hyperthermia 34(8):1289–1297 Otgontuya A, Jeng CJ, Wu TN, Chuang LT, Shen J (2023) Comparison of the treatment efficacies of HIFU, HIFU combined with GnRH-a, and HIFU combined with GnRH-a and LNG-IUS for adenomyosis: a systematic review and meta-analysis. Taiwan J Obstet Gynecol 62(2):226–238. https://doi.org/10.1016/j.tjog.2022.11.009. (PMID: 36965889) Pang L-L, Mei J, Fan L-X et al (2021) Efficacy of high-intensity focused ultrasound combined with GnRH-a for adenomyosis: a systematic review and meta-analysis. Front Public Health 9:688264 Zhao T-T, Pang L-L, Yang L-L et al (2022) Efficacy of high-intensity focused ultrasound combined with LNG-IUS for adenomyosis: a systematic review and meta-analysis. Archiv Gynecol Obstet. https://doi.org/10.1007/s00404-022-06720-z

Acknowledgements

I would first like to thank my teammates, whose expertise was important in reviewing information. I would especially like to thank my supervisor, who formulating the research questions and methodology. Your insightful feedback pushed me to sharpen my thinking and brought my work to a higher level. Finally, I would like to thank my family for always being kind and selfless in providing me with valuable advice and help! Funding This study was supported by the two projects. They are Analysis of real-world-based prognostic factors of HIFU treatment AM and the role of Chinese medicine intervention (2021MS060, Sichuan Provincial Administration of Traditional Chinese Medicine), and Real-world based study on the management of chronic disease in AM patients after HIFU with integrated Chinese and Western medicine (2020KFA3006, State Key Laboratory of Ultrasound in Medicine and Engineering). The funding organization does not have any role in the design or conduct of this study. The authors have no relevant financial or non-financial interests to disclose. Author information Authors and Affiliations Contributions LXF: Manuscript writing, data collection and management, data analysis. YZ: Manuscript editing, data collection and management. LLY: Data collection and management. XLJ: Data collection. YW: Data collection. YFH: Data collection. LS: Data collection. YW: Manuscript editing, Data management, project development. Corresponding author Ethics declarations Conflict of interest All authors disclosed no relevant relationships. Ethics approval This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Hospital of Chengdu University of Traditional Chinese Medicine Research Ethics Committee (No.2021-KL025). Consent to participate Informed consent was obtained from all individual participants included in the study. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. About this article Cite this article Fan, Lx., Zhang, Y., Yang, Ll. et al. Analysis of related factors influencing postoperative recurrence of adenomyosis treated with HIFU. Arch Gynecol Obstet 309, 1765–1773 (2024). https://doi.org/10.1007/s00404-023-07340-x Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s00404-023-07340-x

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

dysmenorrheaadenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis Adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (14)

Cited by (3)

Source provenance

europepmc
last seen: 2026-08-20T06:14:21.026120+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-08-20T06:12:43.061861+00:00
License: CC0 · commercial use OK